13 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 20 Phase 1, 12 Phase 2.
Follow Lymphopenia: new trials by email Literature Review of Lymphopenia trials Research Report on Lymphopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia Recombinant human interleukin (IL) 7-hyFc - Idiopathic CD4 Lymphopenia | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2024-11-06 | 2026-10-19 |
| Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Radiation Therapy, Temozolomide Oral Product - Glioblastoma | Phase 1 / Phase 2 | Active not recruiting | John Flickinger | 2 | 2021-12-14 | 2025-06-18 |
| A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Bempegaldesleukin, Standard of Care, Placebo - Covid-19, Coronavirus Disease 2019 | Phase 1 | Completed | Nektar Therapeutics | 30 | 2020-11-13 | 2024-03-12 |
| Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe) Belimumab - Idiopathic CD4 Lymphopenia | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2020-01-13 | 2026-10-16 |
| Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Laboratory Biomarker Analysis, NT-I7, Placebo - Lymphopenia, Malignant Glioma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2018-10-30 | 2023-10-06 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Thiotepa--single daily dose, Thiotepa--escalated dose - Bone Marrow Failure Syndrome, Thalassemia | Phase 1 / Phase 2 | Completed | University of Florida | 6 | 2018-06-15 | 2023-09-15 |
| Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Autologous CD34+ cells transduced with WASP lentiviral vector - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Active not recruiting | Genethon | 10 | 2014-09-01 | 2021-06-03 |
| Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Abatacept - Hurler Syndrome, Fanconi Anemia | Phase 1 | Completed | Emory University | 10 | 2014-01-01 | 2019-12-26 |
| Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases CD3/CD19 negative allogeneic hematopoietic stem cells - Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 16 | 2013-06-20 | 2025-12-15 |
| Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Retrovirus-mediated gene transfer - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Completed | David Williams | 5 | 2011-07-01 | 2025-08-14 |
| Gene Therapy for WAS Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Completed | Genethon | 5 | 2011-05-01 | 2018-05-22 |
| Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Completed | Genethon | 6 | 2011-03-01 | 2021-06-03 |
| Gene Therapy for Wiskott-Aldrich Syndrome TLT003 - Wiskott-Aldrich Syndrome (WAS) | Phase 1 / Phase 2 | Completed | Fondazione Telethon | 8 | 2010-04-20 | 2025-04-04 |
| Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) CYT107 - Idiopathic CD4+ T-Lymphocytopenia | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2009-02-01 | 2015-10-15 |
| Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Interleukin-2 - Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia | Phase 1 | Completed | Soma Jyonouchi | 9 | 2008-10-01 | 2017-08-16 |
| Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Hematopoietic stem cell transplantation - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Children's Hospital Los Angeles | 25 | 2008-08-01 | 2016-06-23 |
| Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107) - AML, CML | Phase 1 | Completed | Cytheris, Inc. | 12 | 2008-03-01 | 2012-07-26 |
| Safety Study of IL-7 in HIV-infected Patients (Inspire) CYT 107 - HIV Infections, Lymphopenia | Phase 1 | Completed | Cytheris SA | 30 | 2007-05-01 | 2012-10-18 |
| Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Fludarabine, Busulfan, Thymoglobulin - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Completed | The Korean Society of Pediatric Hematology Oncology | 5 | 2007-02-01 | 2014-07-14 |
| Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Hematopoietic stem cell transplantation, Miltenyi CliniMACS selection system, Fludarabine, Melphalan, Thiotepa - Wiskott-Aldrich Syndrome | Phase 1 | Completed | St. Jude Children's Research Hospital | 4 | 2005-05-01 | 2017-04-26 |
Wiskott-Aldrich Syndrome (12) · Granulomatous Disease, Chronic (4) · Anemia, Sickle Cell (3) · Mucopolysaccharidosis I (3) · Primary Immunodeficiency Diseases (3) · T-Lymphocytopenia, Idiopathic CD4-Positive (3) · Anemia, Diamond-Blackfan (2) · Chediak-Higashi Syndrome (2) · Common Variable Immunodeficiency (2) · Lymphohistiocytosis, Hemophagocytic (2) · Lymphoproliferative Disorders (2) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (2) · Severe Combined Immunodeficiency (2) · Thalassemia (2)
Cytopenia (20) · Hematologic Diseases (20) · Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Leukocyte Disorders (20) · Leukopenia (20) · Immunologic Deficiency Syndromes (19) · Blood Coagulation Disorders (12) · Blood Coagulation Disorders, Inherited (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, X-Linked (12) · Hemorrhagic Disorders (12) · Genetic Diseases, Inborn (11) · Primary Immunodeficiency Diseases (9)
efineptakin alfa (3) · Hematopoietic Stem Cell Transplantation (2) · Interleukin-7 (2) · fludarabine (2) · Abatacept (1) · Busulfan (1) · Interleukin-2 (1) · Melphalan (1) · Radiotherapy (1) · Standard of Care (1) · Thiotepa (1) · aldesleukin (1) · belimumab (1) · bempegaldesleukin (1) · thymoglobulin (1)
Genethon (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Children's Hospital Los Angeles (1) · Cytheris SA (1) · Cytheris, Inc. (1) · David Williams (1) · Emory University (1) · Fondazione Telethon (1) · John Flickinger (1) · Nektar Therapeutics (1) · Paul Szabolcs (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Soma Jyonouchi (1) · St. Jude Children's Research Hospital (1) · The Korean Society of Pediatric Hematology Oncology (1)
United States (15) · France (3) · Italy (2) · United Kingdom (2) · Canada (1) · South Korea (1)
Andrea Lisco, M.D. (1) · Biljana Horn, MD (1) · Hisham Abdel-Azim, MD (1) · Hyo Seop Ahn, Ph. D (1) · Irini Sereti (1) · Irini Sereti, M.D. (1) · Jennifer Whangbo, M.D. (1) · Jian L Campian, MD, PhD (1) · John Flickinger, MD (1) · John T Horan, MD (1) · Kimberly Kasow, DO (1) · Marcel van den Brink, MD, PhD (1) · Michael Lederman (1) · Paul Szabolcs, MD (1) · Soma Jyonouchi, MD (1)
PMID 35075289, PMID 23012326, PMID 26675348, PMID 28716862, PMID 30981783, PMID 37244942, PMID 37478401, PMID 38446574, PMID 42777242
2009 (2), UM1CA137443 (1)